Researchers are invited to submit abstracts showcasing innovative research, clinical implementation and advances in cancer genomics. Selected abstracts will be offered either a short talk or a lightning talk.
Â
Please familiarise yourself with the terms and conditions before submission.
Â
The deadline to submit abstracts is 23:59 Friday 18 September.Â
The conference will take place on Level 8 of 20 Water Street, London E14 9QA in Canary Wharf. Further information about accessing the building will be shared closer to the conference. Canary Wharf can be accessed via the Jubilee, Elizabeth and DLR lines and is a short taxi journey from London City Airport.
A range of accommodation options are available in and around Canary Wharf to suit different budgets.
If you are unable to attend, please email events@genomicsengland.co.uk and the Events Team will cancel your registration.
If you have any further questions, please get in touch with the Events Team via email events@genomicsengland.co.uk.
Professor Richard Scott is CEO of Genomics England and Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital/UCL. He specialises in diagnosing rare paediatric disorders and is passionate about applying genomic technologies to patient care. Richard trained at Cambridge and UCL and completed a PhD on childhood cancer syndromes.
Alexandra is a lecturer in Computational Genomics at the University of Edinburgh. Her group applies evolutionary methods to improve variant interpretation for rare disorders and male infertility. Alex joined Genomics England’s Participant Panel in 2024. In her spare time, she enjoys board games, Evolution, and cats.
Hilde Nienhuis is a medical oncologist at Hartwig Medical Foundation and University Medical Center Utrecht. She is project lead of GENAYA, which applies whole genome sequencing to cancers in adolescents and young adults. Her work centres on developing a learning care system in which genomic and clinical data to are combined to guide treatment decisions.
Felix Haglund de Flon, Associate Professor, is Director of Soft Tissue and Bone Pathology at Karolinska University Hospital and research group leader at Karolinska Institutet. His team applies whole genome, transcriptome and methylation profiling to sarcoma diagnostics and biomarker discovery. He has published over 80 peer-reviewed articles.
Ann Nordgren is Professor and Senior Physician of Clinical Genetics at Karolinska Institutet and Gothenburg University, focusing on syndrome and childhood cancer predisposition diagnostics using phenotyping and multi-omics. She coordinates ERN ITHACA for Sweden and has led Genomic Medicine Sweden's Childhood Cancer Predisposition project since 2021, introducing germline sequencing for all children with cancer.
Frédérique Nowak is an engineer graduate of the Ecole Centrale of Paris with a Ph.D. in molecular pharmacology. She was responsible for the coordination of precision oncology programs at the National Cancer Institute. In 2019, she joined Inserm to coordinate the French Genomic Medicine Initiative 2025, a national program aimed at implementing precision medicine in the national healthcare system..
Francisco MartÃnez-Jiménez leads the Computational Immunogenomics Group at the Vall d'Hebron Institute of Oncology (VHIO) and is data mining lead at Hartwig Medical Foundation. His team applies large-scale pan-cancer analysis to tumour evolution, metastasis and their interplay with the immune system, developing improved approaches for cancer diagnosis and patient stratification.
Dr. Julien Vibert is an Assistant Professor at the Drug Development Department and the Cancer Data Science at Gustave Roussy. His work sits at the intersection of clinical oncology and computational science, spanning phase I trials, sarcomas and rare cancers, alongside bioinformatics, single-cell technologies, and AI. He is currently visiting the labs of Pr. Stefan Fröhling and Pr. Jakob Kather in Heidelberg.
Edwin is professor of Human Genetics and scientific director at the Hartwig Medical Foundation in Amsterdam, a non-profit organization that he co-founded 11 years ago with the mission to improve cancer diagnostics and care through genomics and data-driven approaches. Since more than 2 decades he has been pioneering next-generation DNA sequencing technology for advance biological insights and patient care.
Dr. Areeba Patel is Head of Technology at Heidelberg Epignostix and a scientist at the German Cancer Research Center (DKFZ). She leads technology R&D programs focused on translating advances in molecular diagnostics, sequencing and artificial intelligence into rapid, accessible tools for cancer diagnosis and precision oncology.
Jan Korbel is the interim Head of the European Molecular Biology Laboratory (EMBL) Heidelberg. He is also a researcher at the EMBL and the German Cancer Research Center, working at the intersection of genomics, imaging, data science and cancer biology. His research explores the origins of patterns of chromosomal instability and its role in cancer evolution. His lab develops innovative genomic and imaging approaches to obtain a fundamental understanding of the origins of cancer.
Professor. PhD from University of Copenhagen, post doc at EMBL in Heidelberg. Leading computational cancer genomics research group at BRIC/Finsen Laboratory since 2015. Focus on mutational processes and clonal evolution in cancer with a particular focus on genomic structural variations. Lead roles in several national and international cancer genomics consortia including DCCC, BTC, ICGC, PCAWG, PPCG.
Maria Rossing is Chief Physician at MDxCore, Department of Clinical Biochemistry, Rigshospitalet, and Associate Research Professor at the University of Copenhagen. She heads the Rossing Research Group and previously headed the Centre for Genomic Medicine at Rigshospitalet. Her research focuses on cancer genomics, hereditary cancer and precision medicine, translating genomic technologies into clinical cancer care.
Dr Ellen Thomas is the Chief Medical Officer at Genomics England, and a Consultant in Clinical Genetics. Dr Thomas worked on the 100,000 Genomes Project and now focuses on Genomics England’s contributions to the NHS Genomic Medicine Service, leading the Generation Study, and enriching the National Genomic Research Library.
Dr Nirupa Murugaesu is a Consultant Medical Oncologist at Guy’s & St Thomas’ and Cancer Genomics Clinical Director for the South East Genomic Medicine Service. She is Principal Clinician for Cancer Genomics at Genomics England, specialising in colorectal cancer and precision oncology, with national leadership in implementing genomic medicine across the NHS.
Bettina Lundgren is a Clinical Microbiology specialist and Doctor of Medical Science from the University of Copenhagen. Former Center Director at Rigshospitalet, she has over 19 years’ leadership and research experience, including at the US NIH. She chairs several boards and has deep expertise in Danish healthcare and health IT.
Richard Rosenquist Brandell is Professor of Clinical Genetics at Karolinska Institutet and Senior Physician at Karolinska University Hospital in Stockholm. He is Director of Genomic Medicine Sweden (GMS), a national infrastructure for implementation of genomics-based precision medicine in healthcare across the country. He also serves as a Commissioner on the Lancet Commission on Precision Health and is a member of the Nobel Assembly at Karolinska Institutet.